Month: February 2024

– Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups –– Sustained activity with rapid onset within 2 weeks –– Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action –– Favorable safety profile –– 52 week results and Phase 3 CSU trial initiations anticipated in 2024 –– Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory...

  Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticariaLate-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSU Data form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024 Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024 Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipelineParis, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives...

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) — Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. —- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work,...

Toronto, Feb. 23, 2024 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (NEO:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.Faircourt Funds Trading Symbol Distribution Amount(per share/unit) Ex-DividendDate Record Date Payable DateFaircourt Gold Income Corp. FGX $0.024 February 28, 2024 February 29, 2024 March 14, 2024Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. This press release is not for distribution in the United States or over United States wire services. For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or please contact 1-800-831-0304. You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the NEO Exchange...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengthsREYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis,...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.   SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market  SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengthsAlvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries...

Company’s Chief Business Officer elevated to CEO post, effective immediately SINGAPORE, Feb. 23, 2024 (GLOBE NEWSWIRE) — MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a market-leading personal finance aggregation and comparison platform in Greater Southeast Asia, today announced the appointment of Rohith Murthy as its new Chief Executive Officer (“CEO”), effective immediately. Prior to his appointment to CEO, Mr. Murthy served as MoneyHero’s Chief Business Officer, a role he assumed earlier this year following consistent promotions over the course of his nearly ten-year tenure with the Company. “On behalf of the Board, I want to congratulate Rohith, who is the right person to lead the Company forward, on this well-deserved appointment,” said Kenneth Chan, Board Chair and Director with MoneyHero. “Rohith’s deep...

BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) — In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that on February 20, 2024, Mr. Tristram Coffin (the “Investor”) disposed of 800,000 common shares (each a “Share”) of the Corporation. As a result, since the last Form 62-103F1 was filed, the percentage of the Shares of the Issuer controlled by the Investor decreased by 1.98% on an undiluted basis, and by 2.62% on a partially-diluted basis. Immediately before the disposal of the Shares, the Investor exercised control over 8,280,234 Shares of the Issuer, representing ownership of 11.14% on an undiluted basis, and 11.89% on a partially diluted basis. Immediately after the disposal of the Shares, the Investor exercised control over 7,480,234 Shares,...